- Home
- / Regen BioPharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Regen BioPharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.4
2024-10-29
Market Capitalization
$1.9 M
2024-10-29
Revenue
$236.6 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100.0K | 110.0K | 100.0K | 110.0K | 125.5K | 126.6K | 236.6K | 236.6K | ||
| General and administrative expense | 523.9K | 1.7M | 822.1K | 743.8K | 500.6K | 28.1K | 45.0K | 58.9K | ||
| Operating expense total | 547.8K | 2.3M | 2.0M | 1.1M | 546.2K | 186.2K | 317.3K | 212.6K | ||
| EBIT | (706.4K) | (3.0M) | (2.5M) | (1.4M) | (756.8K) | (339.6K) | (686.9K) | (417.2K) | ||
| EBIT margin, % | -2957.0% | -2282.6% | -1425.8% | -688.0% | -270.6% | -542.8% | -176.4% | |||
| Interest income | 233.0 | 1.2K | 1.9K | 10.2K | ||||||
| Interest expense | 295.2K | 455.0 | 58.6K | |||||||
| Pre tax profit | (668.3K) | (1.3M) | ||||||||
| Net Income | (756.4K) | (7.8M) | (5.8M) | (4.7M) | (2.6M) | 2.4M | 1.2M | (668.3K) | (1.3M) | |
| EPS | 0.3 | (0.2) | 0.0 |